iiinova — where your digital self keeps evolving

Monte Rosa Therapeutics @monterosatx.com · 3h

Today, we reported positive results from our Phase 1 study of MRT-8102 in subjects with elevated cardiovascular disease risk. CEO Markus Warmuth shares why these results reinforce our approach to targeting NEK7 upstream in the NLRP3 inflammasome. bit.ly/4rP4jQo

000

Monte Rosa Therapeutics @monterosatx.com · 7h

Join our conference call and webcast today, October 1, at 8:00 a.m. ET. Webcast available here: bit.ly/4xRLpcI

000

Monte Rosa Therapeutics @monterosatx.com · 7h

Today, we announced positive results from our Phase 1 study of MRT-8102, a NEK7-directed molecular glue degrader being developed for NEK7/NLRP3-driven diseases, supporting our plans for Phase 2 studies. bit.ly/4rP4jQo

100

Monte Rosa Therapeutics @monterosatx.com · 22h

Tomorrow at 8:00 a.m. ET, we’ll present results from GFORCE-1, our Phase 1 study of MRT-8102 in subjects with elevated cardiovascular disease risk. Join the webcast to learn more about our pioneering data on the modulation of multiple pathogenic drivers of ASCVD by MRT-8102: bit.ly/4xRLpcI

000

Monte Rosa Therapeutics @monterosatx.com · 25/09/2026

Our CEO, Markus Warmuth, will present at the HBM Biopharma Summit next week in Zurich. Dr. Warmuth will share an update on Monte Rosa’s progress advancing our pipeline of molecular glue degraders and discuss the potential of this approach to address serious diseases.

001

Monte Rosa Therapeutics @monterosatx.com · 16/09/2026

Recent disappointing study results have sparked debate about the role of inflammation in CVD. Our SVP and Head of Translational Biology Manav Korpal explains why it remains a valid target and why we believe the opportunity lies upstream with NEK7/NLRP3: lnkd.in/p/gse_tT2t

lnkd.in

After ZEUS, look upstream: What the biology tells us about cardiovascular disease | Manav Korpal

Like many, I’ve been following the discussion in the aftermath of the ZEUS clinical data, and the subsequent halted ATHENA and HERMES studies. Some have interpreted these events as a condemnation o...

000

Monte Rosa Therapeutics @monterosatx.com · 15/09/2026

This week, our colleague Rodolphe Beaud will present on “Proteome Editing Through Molecular Glue Degraders” at the 2026 Sample Management Symposium. We look forward to exchanging ideas with sample management professionals and technology providers from across the industry.

000

Monte Rosa Therapeutics @monterosatx.com · 10/09/2026

Today, Markus Warmuth, CEO, will provide the latest updates on Monte Rosa’s progress and programs during a fireside chat at the Wells Fargo 21st Annual Healthcare Conference. We hope you can join us in person or online! bit.ly/4A3NiFF

000

Monte Rosa Therapeutics @monterosatx.com · 08/09/2026

Today we announced a milestone achievement associated with the initiation of a Ph 2 study of MRT-6160 (DDY391), a VAV1-directed MGD, in participants living with Sjögren’s disease – the first of several studies expected across immune-mediated diseases: bit.ly/4A0rOcF

010

Monte Rosa Therapeutics @monterosatx.com · 27/08/2026

As summer draws to a close, we’re celebrating our interns in Boston and Basel - and the curiosity, perspectives and collaborative spirit they brought to Monte Rosa. Hear from a few members of this year’s class as they reflect on their experiences. Thank you to all our interns!

010

Monte Rosa Therapeutics @monterosatx.com · 24/08/2026

This milestone builds on encouraging clinical data observed with MRT-2359 in combination with enzalutamide and advances our efforts to evaluate the potential of MRT-2359 for patients with mCRPC with AR mutations.

000

Monte Rosa Therapeutics @monterosatx.com · 24/08/2026

We are proud to announce that the first patient has been dosed in MODeFIRe-1, a Phase 2 study evaluating MRT-2359 in combination with apalutamide in patients with AR mutation-positive metastatic castration-resistant prostate cancer (mCRPC): bit.ly/4cCw8Vw

100

Monte Rosa Therapeutics @monterosatx.com · 06/08/2026

Today, we report financial results and business highlights for the second quarter 2026. CEO Markus Warmuth shares his perspective on our second quarter performance, recent milestones, and the continued momentum across our pipeline. Read more: bit.ly/4fFqdB7

120

Monte Rosa Therapeutics @monterosatx.com · 29/07/2026

At this year’s 3rd Annual Structure-Based Drug Design Summit, Lena Dolgikh will participate on a panel on how to best leverage and combine AI technologies to help make better-informed drug design & development decisions. Learn about the meeting: bit.ly/4gYJLBu

000

Monte Rosa Therapeutics @monterosatx.com · 22/07/2026

Monte Rosa’s Nina Ilic-Widlund and Bill Tahaney present preclinical data on our highly selective CCNE1-targeting molecular glue degrader this week at AACR D3. The data support CCNE1 MGDs as a differentiated precision medicine approach for patients with CCNE1-altered cancers.

011

Monte Rosa Therapeutics @monterosatx.com · 01/07/2026

Adam Cartwright presents preclinical data on MRT-6160 at the Newcastle International Therapeutic Tolerance Workshop. MRT-6160, a first-in-class VAV1 MGD, inhibited disease progression across multiple immune-mediated disease models, reinforcing its broad therapeutic potential.

010

Monte Rosa Therapeutics @monterosatx.com · 11/06/2026

We're proud to be a place where no one has to choose between having a full career and living with total authenticity. We celebrate the LGBTQ+ community and reaffirm our commitment to a workplace where everyone feels valued, supported, and empowered to be themselves. Happy Pride Month! 🏳️‍🌈

000

Monte Rosa Therapeutics @monterosatx.com · 09/06/2026

Important piece in Nature Medicine from Charlotte Harrison on inflammation as a key driver of cardiovascular disease. CMO Filip Janku discusses how our NEK7-directed MGD, MRT-8102, offers a differentiated approach to targeting the NLRP3 inflammasome: go.nature.com/4g9vph6

110

Monte Rosa Therapeutics @monterosatx.com · 04/06/2026

Today, Chief Medical Officer Filip Janku shares updates on Monte Rosa's clinical pipeline and continued momentum across our molecular glue degrader programs in a fireside chat at the Jefferies Global Healthcare Conference in New York. Tune in to learn more: bit.ly/4o5eVbM

010

Monte Rosa Therapeutics @monterosatx.com · 02/06/2026

ICYMI: Two of Monte Rosa’s scientific experts joined @endpts.com Webinars to explore how advances in data science and target prediction are shaping drug discovery – from predicting “gluability” to expanding the universe of potential targets for MGDs: bit.ly/4ugCDDV

010

Monte Rosa Therapeutics @monterosatx.com · 01/06/2026

Excellent article from @bloomberg.com on molecular glue degraders and their potential to target disease-driving proteins once considered "undruggable." Thank you to @robertlangreth.bsky.social for the insightful reporting and inclusion of Monte Rosa: bloom.bg/3Q0AhdI

bloom.bg

Molecular Glue Is Shaping Up to Be the Next Billion-Dollar Cancer Breakthrough

Revolution Medicines’ success in pancreatic cancer has ignited interest in a new type of medicine that's sending dealmaking into overdrive.

010

Monte Rosa Therapeutics @monterosatx.com · 29/05/2026

Georg Petzold and Chao Quan joined @endpts.com Webinars for a discussion on the versatility of molecular glue degraders and the potential of MGDs to unlock new therapeutic opportunities. View the webinar here: bit.ly/4ugCDDV

010

Monte Rosa Therapeutics @monterosatx.com · 27/05/2026

Filip Janku, Chief Medical Officer, will participate in a fireside chat at the TD Cowen Oncology Innovation Summit today at 12pm ET. Join Filip as he discusses our progress advancing molecular glue degraders designed to address critical drivers of cancer. Learn more: bit.ly/4wPg5MA

000

Monte Rosa Therapeutics @monterosatx.com · 21/05/2026

We’re honored to be named an IDEA Pharma “Disruptive Pioneer” in the 2026 Innovation & Invention Index, recognizing the potential of MGDs to drug historically undruggable targets. Thanks to @statnews.com, Allison DeAngelis, and @matthewherper.bsky.social for the coverage: bit.ly/49Gcwyk

bit.ly

Eli Lilly tops prominent rankings on pharma R&D performance

A new set of lists ranks drug company laboratories on two criteria: innovation and invention.

000

Monte Rosa Therapeutics @monterosatx.com · 20/05/2026

We look forward to participating in two upcoming investor conferences – the TD Cowen 7th Annual Oncology Innovation Summit and the Jefferies Global Healthcare Conference in New York. Learn more: bit.ly/4tRW7OB

000

Monte Rosa Therapeutics @monterosatx.com · 11/05/2026

Join Georg Petzold and Chao Quan for an @endpts.com Webinar on Tuesday, May 12 at 10:30am EDT exploring the surprising versatility of molecular glue degraders and the different ways cereblon can engage its targets. To register: bit.ly/4ugCDDV

010

Monte Rosa Therapeutics @monterosatx.com · 07/05/2026

Today, we report financial results and business highlights for the first quarter 2026. CEO Markus Warmuth shares his perspective on the progress behind these results and the momentum across our pipeline. Read more: bit.ly/3P0tv7v

000

Monte Rosa Therapeutics @monterosatx.com · 05/05/2026

Monte Rosa’s Chief Data & Information Officer, John Castle, is presenting at the Swiss Biotech Showcase this week in Basel – sharing how we’re advancing our pipeline and expanding molecular glue degraders to address previously undruggable targets. If you’re attending, we look forward to connecting.

010

Monte Rosa Therapeutics @monterosatx.com · 22/04/2026

ICYMI: We shared preclinical data on our CCNE1-directed MGD at #AACR26, highlighting a potential first-in-class approach to a frequently amplified driver oncogene. We believe MRT-55811 has the potential to provide clinical benefit across CCNE1-amplified cancers: bit.ly/4eHzTe2

000

Monte Rosa Therapeutics @monterosatx.com · 20/04/2026

We’re presenting preclinical data at #AACR26 on the potential of our CCNE1-directed molecular glue degrader to treat CCNE1-amplified solid tumors, suggesting a potential new approach to a historically undruggable target. Learn more: bit.ly/48dRoil

000

Monte Rosa Therapeutics @monterosatx.com · 16/04/2026

The panel discussion will cover the opportunities and challenges for molecular glues, which have gone from serendipitous discovery to rational design to the clinic in near-record time – and we're only scratching the surface of their potential. We hope to see you in San Diego!

000

Monte Rosa Therapeutics @monterosatx.com · 16/04/2026

We’re hitting the road and heading to #AACR2026. There, CEO Markus Warmuth will join a panel of biopharma leaders pioneering proximity-induced therapies: bit.ly/4te6LQ2

110

Monte Rosa Therapeutics @monterosatx.com · 14/04/2026

Maciej Cabanski presents today at the 20th WRIB on biomarker modalities in the early development of MGDs for immune mediated diseases and oncology, highlighting advances in clinical biomarker strategies for targeted protein degradation.

010

Monte Rosa Therapeutics @monterosatx.com · 26/03/2026

It’s a reminder that the future of research depends on inviting people in early, encouraging them to stay curious, and making space for them to lead. As we celebrate Women’s History Month, we’re inspired by the scientists of tomorrow and committed to expanding pathways into science.

000

Monte Rosa Therapeutics @monterosatx.com · 26/03/2026

We’re delighted to have volunteered with Science Club for Girls this month, supporting their mission to increase access to STEM education and empower the next generation of girls and gender-expansive youth to see themselves in science.

100

Monte Rosa Therapeutics @monterosatx.com · 17/03/2026

Today, we report business highlights and financial results for the fourth quarter and full year of 2025. Read more: bit.ly/47240Zf

010

Monte Rosa Therapeutics @monterosatx.com · 11/03/2026

The discussion covered Markus’ history as a drug developer, why he is such a believer in MGDs, and what success might mean for patient care and for the biopharma industry. Listen to the full episode here: bit.ly/4cHTXMK

000

Monte Rosa Therapeutics @monterosatx.com · 11/03/2026

Jonathan Grinstein of Inside Precision Medicine had a wide-ranging conversation with our CEO, Markus Warmuth, for the “Behind the Breakthroughs” podcast, highlighting how we expect 2026 to be a breakthrough year for Monte Rosa and molecular glue degraders.

100

Monte Rosa Therapeutics @monterosatx.com · 10/03/2026

Filip Janku, CMO, will field questions on Monte Rosa’s progress and programs during a fireside chat today at the Barclays 28th Annual Global Healthcare Conference. We hope you can join us! bit.ly/4umolCx

000

Monte Rosa Therapeutics @monterosatx.com · 04/03/2026

Autoimmune diseases affect millions, yet many individuals still lack effective treatment options. At Monte Rosa, we’re harnessing MGDs to expand what’s possible in autoimmune care. Learn more this Autoimmune Awareness Month: bit.ly/409ianC

010

Monte Rosa Therapeutics @monterosatx.com · 02/03/2026

Our CEO, Markus Warmuth, will provide an overview on recent progress and clinical data from our pipeline programs, including our NEK7 and GSPT1-directed degraders, today at the TD Cowen Health Care Conference. bit.ly/3OAtyXb

020

Monte Rosa Therapeutics @monterosatx.com · 27/02/2026

We’re turning scientific insight into meaningful progress for heart health – advancing a new way to treat inflammation in ASCVD by targeting the NLRP3/NEK7 pathway upstream. Our NEK7-directed molecular glue degrader, MRT-8102, is designed to stop NLRP3 activation at the source.

010

Monte Rosa Therapeutics @monterosatx.com · 25/02/2026

CMO, Filip Janku, comments on our updated MRT-2359 data, which supports initiation of a new Phase 2 study this year to evaluate MRT-2359 in combination with a second-generation AR inhibitor in mCRPC patients with AR mutations. bit.ly/4aO3E9B

020

Monte Rosa Therapeutics @monterosatx.com · 24/02/2026

Today, we announced updated, positive clinical data from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC). bit.ly/4aPUt8P

000

Monte Rosa Therapeutics @monterosatx.com · 19/02/2026

Activation of the NLRP3 inflammasome promotes plaque growth and destabilization, and NEK7 is central to NLRP3 inflammasome assembly. This biology is increasingly recognized as a key driver of ASCVD – and a promising target for next-generation cardiovascular therapies.

010

Monte Rosa Therapeutics @monterosatx.com · 19/02/2026

It’s not “just” cholesterol. The role of inflammation in atherosclerotic cardiovascular disease (ASCVD) is gaining increased attention.

110

Monte Rosa Therapeutics @monterosatx.com · 11/02/2026

On International Day of Women and Girls in Science, we’re celebrating the individuals advancing scientific innovation. From Boston to Basel, women at Monte Rosa are turning insight into impact for patients and the next generation. Learn more: bit.ly/4krQLX8 #February11

000

Monte Rosa Therapeutics @monterosatx.com · 09/02/2026

ASCVD affects 40M+ people in the U.S. and is the leading cause of death worldwide, yet many are unfamiliar with it. Caused by plaque buildup in the arteries, it can lead to heart attack and stroke. This Heart Health Month, learn more from @americanheart.bsky.social: bit.ly/3LCK8o7

010

Monte Rosa Therapeutics @monterosatx.com · 04/02/2026

On #WorldCancerDay, we’re proud to stand #UnitedByUnique. At Monte Rosa, our paths into oncology may differ, but we’re united in pushing drug discovery forward with the goal to develop precision treatments for people living with cancer. Learn more: bit.ly/4qfnEHW

020

Monte Rosa Therapeutics @monterosatx.com · 26/01/2026

ICYMI: Adam Cartwright presented findings at #KSAutoimmune26 on MRT-6160 in multiple immune-mediated disease models. Thanks to @keystonesymposia.bsky.social for convening such a rich and engaging event. View the presentation here: bit.ly/4bk9dP0

011